Cyclo Therapeutics (CYTHW) News Today

$0.22
-0.05 (-18.52%)
(As of 04/22/2024)
SourceHeadline
businesswire.com logoCyclo Therapeutics Announces Publication of Positive Data from Phase 2 Clinical Study of Trappsol ® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1
businesswire.com - June 29 at 8:22 PM
finance.yahoo.com logoCyclo Therapeutics Announces Publication of Positive Data from Phase 2 Clinical Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1
finance.yahoo.com - June 29 at 3:22 PM
Get Cyclo Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CYTHW and its competitors with MarketBeat's FREE daily newsletter.

His win rate puts Warren Buffett to shame… (Ad)

Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.

Click here now for the full story.

CYTHW Media Mentions By Week

CYTHW Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CYTHW
News Sentiment

0.00

0.33

Average
Medical
News Sentiment

CYTHW News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CYTHW Articles
This Week

0

0

CYTHW Articles
Average Week

Get Cyclo Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CYTHW and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:CYTHW) was last updated on 4/29/2024 by MarketBeat.com Staff

From Our Partners